Actuate Therapeutics Inc. has announced new data from its Phase 2 clinical trial evaluating elraglusib in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The results were presented in both oral and poster sessions at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9, 2026. The study met its primary endpoint, demonstrating a statistically significant improvement in overall survival for patients receiving the elraglusib combination compared to chemotherapy alone. The elraglusib combination reduced the risk of death by 38% compared to gemcitabine/nab-paclitaxel alone, with increased durable survival observed beyond 24 months. As of November 2025, seventeen patients remain alive in the elraglusib combination arm, with three patients surpassing the 24-month survival mark, while no patients remain on chemotherapy alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623578) on January 12, 2026, and is solely responsible for the information contained therein.